Giorgio Massimini
CMO CanWell Pharma Inc
Giorgio Massimini is the Chief Medical Officer at CanWell Pharma. He has over 40 years of experience in leading clinical research & development projects. He has developed 20+ drugs in his career and has led their clinical development to approval in US, EU and other countries or to licensing. He is a member of several scientific societies and authored or co-authored over 60 papers or abstracts and eight patents.
Seminars
Wednesday 14th October 2026
Spotlighting Clinical Performance of CAN1012: A TLR7 Agonist for the Treatment of PD-1 Refractory Melanoma & Dedifferentiated Liposarcoma
2:00 pm
- Introducing CAN1012 small molecule drug conjugate with TLR7 agonist immunomodulatory payload
- Laying out rationale for liposarcoma indication selection and CAN1012 early clinical data leading to Orphan Drug Designation
- Understanding the importance of indication selection in underserved cancer indications to maximize ADC first line potential and patient impact
